… , to evaluate the treatment efficacy and associated prognostic … LM indicated a worse outcome
compared to those without LM… LM as a third-line or further therapy, when compared with …

… conducted to compare the relative efficacy of gefitinib, erlotinib, … NMA of the efficacy of first-line
gefitinib, erlotinib, afatinib, … the second- and third-line treatment strategies after TKI failure […

… (EGFR-TKI) (gefitinib and erlotinib) [6]. This study is aimed at … in second-line or thirdline
treatment for advanced NSCLC [7]. … compared the efficacy and safety of gefitinib and pemetrexed …

… with efficacy as a post-first-line and as a second/third-line … efficacy and survival compared
to treatment with cytotoxic … -generation EGFR-TKIs (gefitinib and erlotinib) who presented with …

… subsequently received EGFR-TKIs as third-line treatment. … were administered erlotinib
after initial gefitinib treatment. The … phase III trial comparing gefitinib with carboplatin-paclitaxel …

… and efficacy for advanced non-small cell lung cancer (NSCLC). The study goals were: to
compare the uptake of systemic therapy … who received second and third line therapy had initially …

… of differences in detection platforms and antibodies, tumor … therapy, 60 patients (54.05%)
received the first-line treatment… treatment, and 15 patients (13.51%) the third-line treatment. …

… , gefitinib, and erlotinib in first-line therapy is … comparison to evaluate the efficacy and
safety differences between tislelizumab and pembrolizumab in first-line treatment for advanced …

… and efficacy of concurrent gefitinib and durvalumab for the … in PFS or ORR compared to that
previously reported with gefitinib … In a small Phase 1b study of erlotinib plus atezolizumab, …

… compared with TP53 wild-type patients (34). In another study, TP53 co-mutation was discovered
as a predictor for TKI efficacy … approved as a third-line treatment for advanced NSCLC in …